SellYourAIData
Get a free valuation Contact

AI Data Deal TrackerDeal brief

×

Tempus expands Gilead's enterprise-wide access to its oncology data library

Tempus and Gilead announced an expanded multi-year collaboration giving Gilead enterprise-wide access to Tempus's de-identified multimodal data through its Lens platform, starting with oncology. No value was disclosed.

April 9, 2026 Tempus and Gilead announced an expanded multi-year collaboration giving Gilead enterprise-wide access to Tempus's de-identified multimodal data through its Lens platform, starting with oncology.1

Terms of the deal

Tempus announced a strategic collaboration with Gilead Sciences on April 9, 2026, described as an expanded, multi-year effort to build and advance Gilead's oncology pipeline.1

Gilead gets enterprise-wide access to Tempus's Lens platform, broader datasets across multiple indications and dedicated analytical services.1 The release does not state a duration or a value.1

Background

Gilead was already using Tempus's de-identified multimodal data before the expansion.1 Tempus announced a similar collaboration with Merck on March 3, 2026.2

An independent analysis by IntuitionLabs estimates the Gilead value at $50 million to $150 million, but it labels that figure its own estimate. It reports that Tempus CEO Eric Lefkofsky called the deal "quite large" and "smaller than Merck" on an earnings call.2

What it means for data sellers

A data owner with a large, linked clinical library can sell enterprise access with analytics services rather than single datasets. Buyers that already use the data are the likeliest to expand.

How the deal came together

  1. Gilead is already a customer. Gilead had used Tempus's de-identified multimodal data for trial design, indication selection, biomarker strategy, health outcomes analysis and clinical real-world evidence.
  2. The collaboration is expanded. On April 9, 2026, the companies announced an expanded multi-year collaboration.
  3. Broader access. Gilead gets enterprise-wide access to the Lens platform, broader datasets across multiple indications and dedicated Tempus analytical services.
  4. No value stated. The release gives no duration beyond multi-year and no financial value.

Takeaways for companies with data

  • Data licenses to pharma are increasingly sold as platform access plus services, not as a file transfer.
  • Existing customers expand their access over time, so a first license can lead to larger enterprise terms.
  • Dollar figures in analyst write-ups are estimates; neither company has stated a value.

Sources

Every numbered reference above points to an entry here. Figures come from these pages as of the date shown at the top of the article. Where a source reports a number it got from unnamed people, the text says so.

  1. Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE (Tempus press release, as reproduced by 1st Oncology, April 2026)
  2. Tempus AI RWD Deals: Merck and Gilead 2026 Pricing Analysis (IntuitionLabs, 2026)

###

About the AI Data Deal Tracker

SellYourAIData tracks publicly reported sales and licenses of data to AI companies, with the price, terms and sources for each. Entries are checked against public reporting and updated as deals change. SellYourAIData was not involved in this deal. To ask what your company's data could sell for, get a free valuation. To report a deal, contact us.